SAB Biotherapeutics Inc. (SABS)
SAB Biotherapeutics Statistics
Share Statistics
SAB Biotherapeutics has 9.29M shares outstanding. The number of shares has increased by 0% in one year.
| Shares Outstanding | 9.29M |
| Shares Change (YoY) | 0% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 5.11% |
| Shares Floating | 7.49M |
| Failed to Deliver (FTD) Shares | 781 |
| FTD / Avg. Volume | 0.73% |
Short Selling Information
The latest short interest is 92.67K, so 1% of the outstanding shares have been sold short.
| Short Interest | 92.67K |
| Short % of Shares Out | 1% |
| Short % of Float | 1.32% |
| Short Ratio (days to cover) | 5.09 |
Valuation Ratios
The PE ratio is -1.03 and the forward PE ratio is -0.44. SAB Biotherapeutics's PEG ratio is 0.02.
| PE Ratio | -1.03 |
| Forward PE | -0.44 |
| PS Ratio | 26.54 |
| Forward PS | 0.1 |
| PB Ratio | 1.35 |
| P/FCF Ratio | -1.02 |
| PEG Ratio | 0.02 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for SAB Biotherapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.98, with a Debt / Equity ratio of 0.18.
| Current Ratio | 2.98 |
| Quick Ratio | 2.98 |
| Debt / Equity | 0.18 |
| Debt / EBITDA | -0.11 |
| Debt / FCF | -0.14 |
| Interest Coverage | -134.77 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $20.99K |
| Profits Per Employee | $-541.35K |
| Employee Count | 63 |
| Asset Turnover | 0.03 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -69.72% in the last 52 weeks. The beta is 0.53, so SAB Biotherapeutics's price volatility has been higher than the market average.
| Beta | 0.53 |
| 52-Week Price Change | -69.72% |
| 50-Day Moving Average | 1.55 |
| 200-Day Moving Average | 2.68 |
| Relative Strength Index (RSI) | 42.75 |
| Average Volume (20 Days) | 106.75K |
Income Statement
In the last 12 months, SAB Biotherapeutics had revenue of 1.32M and earned -34.11M in profits. Earnings per share was -3.68.
| Revenue | 1.32M |
| Gross Profit | 1.32M |
| Operating Income | -42.91M |
| Net Income | -34.11M |
| EBITDA | -42.91M |
| EBIT | -34.42M |
| Earnings Per Share (EPS) | -3.68 |
Balance Sheet
The company has 8.9M in cash and 4.67M in debt, giving a net cash position of 4.23M.
| Cash & Cash Equivalents | 8.9M |
| Total Debt | 4.67M |
| Net Cash | 4.23M |
| Retained Earnings | -124.17M |
| Total Assets | 44.2M |
| Working Capital | 15.81M |
Cash Flow
In the last 12 months, operating cash flow was -34.29M and capital expenditures 0, giving a free cash flow of -34.29M.
| Operating Cash Flow | -34.29M |
| Capital Expenditures | 0 |
| Free Cash Flow | -34.29M |
| FCF Per Share | -3.7 |
Margins
Gross margin is 100%, with operating and profit margins of -3244.87% and -2579.03%.
| Gross Margin | 100% |
| Operating Margin | -3244.87% |
| Pretax Margin | -2579.03% |
| Profit Margin | -2579.03% |
| EBITDA Margin | -3244.87% |
| EBIT Margin | -3244.87% |
| FCF Margin | -2593.15% |
Dividends & Yields
SABS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for SABS is $9.5, which is 619.7% higher than the current price. The consensus rating is "Buy".
| Price Target | $9.5 |
| Price Target Difference | 619.7% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
Stock Splits
The last stock split was on Jan 5, 2024. It was a backward split with a ratio of 1:10.
| Last Split Date | Jan 5, 2024 |
| Split Type | backward |
| Split Ratio | 1:10 |
Scores
| Altman Z-Score | -5.56 |
| Piotroski F-Score | 1 |